NA
MRVI icon

NewEdge Advisors’s Maravai LifeSciences MRVI Stock Holding History

NewEdge Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46
Closed -$150 – 4293
2025
Q4 		$150 Hold
46
– – ﹤0.01% 4147
2025
Q3 		$132 Hold
46
– – ﹤0.01% 4023
2025
Q2 		$111 Hold
46
– – ﹤0.01% 3901
2025
Q1 		$102 Sell
46
-11
-19% -$43 ﹤0.01% 3827
2024
Q4 		$311 Hold
57
– – ﹤0.01% 3715
2024
Q3 		$473 Hold
57
– – ﹤0.01% 3608
2024
Q2 		$408 Sell
57
-362
-86% -$3.13K ﹤0.01% 3587
2024
Q1 		$3.63K Sell
419
-189
-31% -$1.28K ﹤0.01% 3245
2023
Q4 		$3.98K Buy
608
+562
+1,222% +$3.63K ﹤0.01% 3184
2023
Q3 		$460 Sell
46
-117
-72% -$1.28K ﹤0.01% 3265
2023
Q2 		$2.03K Buy
163
+117
+254% +$1.58K ﹤0.01% 3092
2023
Q1 		$644 Sell
46
-37
-45% -$531 ﹤0.01% 3216
2022
Q4 		$530 Buy
+83
New +$1.31K ﹤0.01% 3157

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewEdge Advisors's MRVI Position: Q1 2026 in Review

NewEdge Advisors sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 46 shares — an estimated $150 sold.

NewEdge Advisors first reported a position in MRVI in Q4 2022 and held it in 13 quarters. The position peaked at $3.98K in Q4 2023. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • NewEdge Advisors reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
  • NewEdge Advisors sold 46 Maravai LifeSciences shares in Q1 2026, an estimated $150.
  • NewEdge Advisors first reported a position in Maravai LifeSciences in Q4 2022 and held it in 13 quarters.
  • NewEdge Advisors's Maravai LifeSciences position peaked at $3.98K in Q4 2023.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.